ArticleBMC women's health2026
Clinicopathological characteristics and prognostic analysis of synchronous endometrioid endometrial and ovarian carcinomas: a retrospective cohort study.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSynchronous endometrioid endometrial and ovarian carcinomas (SEEOCs) represent a small yet clinically significant entity of gynecological malignancies. Their clinicopathological correlations, immunohistochemical profiles, and prognosis have not been well established.
methodsWe conducted a retrospective analysis of 50 SEEOC cases identified among 1160 patients with endometrioid endometrial carcinoma at a single institution. Clinicopathological parameters, including immunohistochemical profiles, were evaluated. Progression-free survival (PFS) was analyzed, with Kaplan-Meier analysis performed to identify significant prognostic factors.
resultsDeficient mismatch repair (dMMR) was detected in 36.1% of SEEOC cases and mutant p53 expression in 13.2%. PD-L1 (22C3) positivity was observed in 63.0% cases, and HER2 expression in 75.0%. Factors associated with worse PFS included poor tumor differentiation, > 50% myometrial invasion, lymphovascular space invasion (LVSI), lymph node metastasis, and advanced 2023 FIGO stage. Kaplan-Meier pairwise comparisons revealed that patients with focal LVSI had a PFS comparable to that of patients with substantial LVSI. Five patients were classified as FIGO IA3 stage. All patients at IA3 stage were premenopausal, showed no MELF (microcystic, elongated, and fragmented) invasion pattern, and none had recurrence.
conclusionsThese findings support the prognostic significance of poor tumor differentiation, > 50% myometrial invasion, LVSI, lymph node metastasis, and 2023 FIGO staging system in SEEOCs. The high rates of dMMR, HER2, and PD-L1 positivity in SEEOCs suggest potential for targeted therapies in future therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.